

ViroMed Laboratories' IVF Panels

1. FDA Guidance Female No Reflex (139060)

- a. 138874, HBsAg
- b. 138699, HBcore Total
- c. 138907, HCV
- d. 138948, HIV-1/HIV-2 plus O
- e. 138726, RPR with reflex to FTA
- f. 138828, CT/NG NAA
- g. 138687, HIV-1/HCV NAT

2. FDA Guidance Female With Reflex (139061)

- a. 138749, HBsAg with reflex to confirmatory neutralization assay
- b. 138979, HBcore Total with reflex to IgM
- c. 138915, HCV with reflex to confirmatory RIBA
- d. 138931, HIV-1/HIV-2 plus O with reflex to HIV-1 WB
- e. 138726, RPR with reflex to FTA
- f. 138828, CT/NG NAA
- g. 138687, HIV-1/HCV NAT

3. FDA Guidance Male No Reflex (139062)

- a. 138874, HBsAg
- b. 138699, HBcore Total
- c. 138907, HCV
- d. 138948, HIV-1/HIV-2 plus O
- e. 138726, RPR with reflex to FTA
- f. 138922, HTLV I/II
- g. 138662, CMV Total
- h. 138828, CT/NG NAA
- i. 138687, HIV-1/HCV NAT

4. FDA Guidance Male With Reflex (139063)

- a. 138749, HBsAg with reflex to confirmatory neutralization assay
- b. 138979, HBcore Total with reflex to IgM
- c. 138915, HCV with reflex to confirmatory RIBA
- d. 138931, HIV-1/HIV-2 plus O with reflex to HIV-1 WB
- e. 138726, RPR with reflex to FTA
- f. 138780, HTLV I/II with reflex to Immunoblot
- g. 138697, CMV Total with reflex to IgM
- h. 138828, CT/NG NAA
- i. 138687, HIV-1/HCV NAT

5. FDA Guidance Female No Reflex No CT/NG (139036)

- a. 138874, HBsAg
- b. 138699, HBcore Total
- c. 138907, HCV
- d. 138948, HIV-1/HIV-2 plus O
- e. 138726, RPR with reflex to FTA
- f. 138687, HIV-1/HCV NAT

ViroMed Laboratories' IVF Panels (continued)

- 6. FDA Guidance Female With Reflex No CT/NG (139065)**
 - a. 138749, HBsAg with reflex to confirmatory neutralization assay
 - b. 138979, HBcore Total with reflex to IgM
 - c. 138915, HCV with reflex to confirmatory RIBA
 - d. 138931, HIV-1/HIV-2 plus O with reflex to HIV-1 WB
 - e. 138726, RPR with reflex to FTA
 - f. 138687, HIV-1/HCV NAT

- 7. FDA Guidance Male No Reflex No CT/NG (139066)**
 - a. 138874, HBsAg
 - b. 138699, HBcore Total
 - c. 138907, HCV
 - d. 138948, HIV-1/HIV-2 plus O
 - e. 138726, RPR with reflex to FTA
 - f. 138922, HTLV I/II
 - g. 138662, CMV Total
 - h. 138687, HIV-1/HCV NAT

- 8. FDA Guidance Male With Reflex No CT/NG (139067)**
 - a. 138749, HBsAg with reflex to confirmatory neutralization assay
 - b. 138979, HBcore Total with reflex to IgM
 - c. 138915, HCV with reflex to confirmatory RIBA
 - d. 138931, HIV-1/HIV-2 plus O with reflex to HIV-1 WB
 - e. 138726, RPR with reflex to FTA
 - f. 138780, HTLV I/II with reflex to Immunoblot
 - g. 138697, CMV Total with reflex to IgM
 - h. 138687, HIV-1/HCV NAT

- 9. FDA Guidance Female No Reflex plus HTLV (139068)**
 - a. 138874, HBsAg
 - b. 138699, HBcore Total
 - c. 138907, HCV
 - d. 138948, HIV-1/HIV-2 plus O
 - e. 138726, RPR with reflex to FTA
 - f. 138828, CT/NG NAA
 - g. 138687, HIV-1/HCV NAT
 - h. 138922, HTLV I/II

- 10. FDA Guidance Female With Reflex plus HTLV (139069)**
 - a. 138749, HBsAg with reflex to confirmatory neutralization assay
 - b. 138979, HBcore Total with reflex to IgM
 - c. 138915, HCV with reflex to confirmatory RIBA
 - d. 138931, HIV-1/HIV-2 plus O with reflex to HIV-1 WB
 - e. 138726, RPR with reflex to FTA
 - f. 138828, CT/NG NAA
 - g. 138687, HIV-1/HCV NAT
 - h. 138780, HTLV I/II with reflex to Immunoblot